Lipoprotein(a) (Lp(a)) has been established as an independent, likely causal risk factor for incident AS.4–6 Interventions aimed at lowering Lp(a), including proprotein convertase subtilisin/kexin type 9 inhibitors and apolipoprotein(a) antisense therapies, may be effective in delaying or preventing AS progression.7 However, the optimal timing of medical intervention in AS remains unresolved. Here, LPA is linked to aortic stenosis.